Reaction
Glucocorticoid Deficiency reporting signals
As of the last recalculation, Glucocorticoid Deficiency appears in 410 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 67.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 105 | 67.8 | 67.8 |
| Ipilimumab | 38 | 49.2 | 49.2 |
| Posaconazole Delayed-Release | 9 | 42.5 | 42.5 |
| Nivolumab | 64 | 39.6 | 39.7 |
| Paclitaxel (Aibumin-Bound) | 49 | 34.2 | 34.3 |
| Posaconazole | 10 | 32.0 | 32.0 |
| Pemetrexed | 13 | 31.8 | 31.8 |
| Carboplatin | 62 | 29.0 | 29.0 |
| Paclitaxel | 49 | 28.4 | 28.4 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 5 | 25.5 | 25.5 |
| Granisetron | 5 | 24.5 | 24.5 |
| Abiraterone | 6 | 22.7 | 22.7 |
| Pemetrexed Disodium | 13 | 17.9 | 17.9 |